BioAdaptives

BioAdaptives Book Value per Share

The Book Value per Share of BioAdaptives (BDPT) as of Oct 26, 2026 is -0.26 USD. In the previous year, Book Value per Share was -0.18 USD — a change of 45.50% (lower).

Book Value per Share

-0.26USD

YoY

45.50%

Last updated:

Book Value per Share of BioAdaptives is 2025 -0.26 USD. Book Value per Share of BioAdaptives was 2024 -0.18 USD. It decreases by 45.50% lower compared to the previous year.

The BioAdaptives Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
-0.08 USD
Jan 1, 2019
-0.10 USD
Jan 1, 2020
-0.17 USD
Jan 1, 2021
-0.13 USD
Jan 1, 2022
-0.18 USD
Jan 1, 2023
-0.20 USD
Jan 1, 2024
-0.18 USD
Jan 1, 2025
-0.26 USD
The BioAdaptives Book Value per Share history
YEARBook Value per ShareYoY
-0.26USD+45.50%
-0.18USD-11.10%
-0.20USD+13.44%
-0.18USD+32.79%
-0.13USD-20.72%
-0.17USD+64.17%
-0.10USD+21.06%
-0.08USD-19,892.90%
0.00USD-101.99%
-0.02USD-13.28%
-0.02USD+173,723.93%
-0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

Book Value per Share of BioAdaptives is -0.26 USD in 2025.

Book Value per Share of BioAdaptives changed from -0.18 USD to -0.26 USD, representing a 45.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioAdaptives

All Key Metrics — BioAdaptives